Metagenomi, Inc. Reports Q2 2025 Financial Results

Metagenomi, Inc. ( (MGX) ) has released its Q2 earnings. Here is a breakdown of the information Metagenomi, Inc. presented to its investors.

Metagenomi, Inc. is a precision genetic medicines company based in Emeryville, California, specializing in developing curative therapeutics using a proprietary genome editing toolbox derived from metagenomics, primarily operating in the biotechnology sector.

In its latest earnings report for the quarter ended June 30, 2025, Metagenomi, Inc. reported a net loss of $19.9 million, with total revenue from collaborations amounting to $8.5 million. The company continues to focus on advancing its research and development programs, despite the financial challenges reflected in its quarterly results.

Key financial highlights include a decrease in collaboration revenue from $20 million in the same quarter last year to $8.5 million, and a significant reduction in operating expenses from $36.9 million to $29.5 million. The company also reported a comprehensive loss of $20.2 million, with its cash and cash equivalents slightly decreasing to $26.9 million from $27.4 million at the end of 2024.

Despite the financial losses, Metagenomi remains committed to its strategic initiatives, including the development of its genome editing technology and maintaining its collaborations. The company has regained full rights to its base editing and RNA-mediated integration systems following the termination of its agreement with Moderna.

Looking ahead, Metagenomi’s management remains focused on leveraging its genome editing platform to advance its pipeline and achieve long-term growth, while navigating the challenges of the current economic environment.